Skip to main content
SpringerLink
Log in

High-Dose Chemotherapy for Small Cell Lung Cancer

  • Chapter
Lung Cancer: Basic and Clinical Aspects

Part of the book series: Cancer Treatment and Research ((CTAR,volume 28))

Abstract

Initially, the introduction of chemotherapy in the treatment of small cell lung cancer (SCLC) has considerably improved the bad prognosis of the patients with this highly malignant tumor [1]. The change of a median survival of less than 3 months before chemotherapy into more than one year as a result of its introduction, and the observation of the occurrence of two year disease free survival, be it only in a small number of patients, led half a decade ago to speculations that the goal of cure in a larger number of these patients might be within reach [2]. Since that time however, no further progress has been made and the therapeutic results are still on the same plateau as five years ago. This disappointing reality necessitates the investigation of other therapeutic approaches and in this chapter the results of high-dose chemotherapy (HDCT) will be summarised and discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Weiss RB: Small-cell carcinoma of the lung: therapeutic management. Ann Intern Med, 88:522–531, 1978.

    PubMed  CAS  Google Scholar 

  2. Oldham RK, Greco FA: Small-cell lung cancer. A curable disease. Cancer Chemother Pharmacol 4:173–177.

    Google Scholar 

  3. Postmus PE, Holthuis JJM, Haaxma-Reiche H, Mulder NH, Vencken LM, van Oort WJ, Sleijfer DTh, Sluiter HJ: Penetration of VP 16–213 into cerebrospinal fluid after high dose intravenous administration. J Clin Oncol 2:215–220, 1984.

    PubMed  CAS  Google Scholar 

  4. Postmus PE, Haaxma-Reiche H, Vencken LM, Meinesz AF, Sleijfer DTh, Mulder NH: A complete remission of brain metastases of small cell lung cancer after high-dose chemotherapy. Ann Int Med, 101:717, 1984.

    PubMed  CAS  Google Scholar 

  5. Philips GL, Fay JW, Herzig GP, Herzig RH, Werner RS, Wolff SN, Lazarus HM, Karanes C, Ross WE, Kramer BS, the south eastern cancer study group: Intensive l,3-bis(2-chlor-oethyl)-1 -nitrosurea (BCNU), NSC 4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study. Cancer 52:1792–1802, 1983.

    Article  Google Scholar 

  6. Griswold DP, Laster WR, Snow MY, Schabel FM, Skipper HE: Experimental evaluation of potential anticancer agents. XII Quantitative drug response of the SA 180, CA 755, L 1210 system to a standard list of active anti-cancer agents. Cancer Research, 23 part 2:271–519, 1963.

    Google Scholar 

  7. Schabel FM, Skipper ME, Trader MW, Laster WR, Corbett TH, Grisworld DP: Concepts for controlling drug resistant tumor cells. In: Breast Cancer. Experimental and clinical aspects. Pergamon Press, Oxford, 1980.

    Google Scholar 

  8. Steel GG: Growth and survival of tumor stem cells. In: Growth kinetics of tumors. Oxford. Clarendon Press, 244–267, 1977.

    Google Scholar 

  9. Thomas ED, Buckner CD, Clift RA: Marrow transplantation for acute non-lymphoblastic leukemia in first remission. N Engl J Med 301:597–599, 1979.

    Article  PubMed  CAS  Google Scholar 

  10. Philip T, Biron P, Herré P, Duton L, Ehrsam A, Philip I, Souillet E, Plouvier E, Le Mevel A, Philippe N, Kuran O, Bachmann P, Cordier JF, Freycon F, Brunat-Mentigny M: Massive BACT chemotherapy with autologous bone marrow transplantation in 17 cases of NHML with very bad prognosis. Eur J Cancer 19:1371–1379, 1983.

    CAS  Google Scholar 

  11. Appelbaum FR, Deisseroth AB, Graw RG, Herzig GP, Levine AS, Magrath IT, Pizzc PA, Poplaek DG, Ziegler JL: Prolonged complete remission following high-dose chemotherapy of Burkitt’s lymphoma in relapse. Cancer 41:1059–1063, 1978.

    Article  PubMed  CAS  Google Scholar 

  12. Cohen MH, Creaven PJ, Fossieck BE, Broder LE, Selawry OS, Johnston AV, Williams CL, Minna JD: Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 61:349–354, 1977.

    PubMed  CAS  Google Scholar 

  13. Broder LE, Cohen MH, Selawry OS: Treatment of bronchogenic carcinoma II. Small cell. Cancer Treat Rev 4:219–260, 1977.

    Article  PubMed  CAS  Google Scholar 

  14. Issell BF: The podophyllotoxin derivatives VP 16–213 and VM 26. Review. Cancer Chemother Pharmacol 7:73–80, 1982.

    PubMed  CAS  Google Scholar 

  15. Souhami RL, Harper PG, Linch D, Trask C, Goldstone AH, Tobias JS, Spiro SG, Geddes DM, Richards JDM: High-dose cyclophosphamide with autologous marrow transplantation for small cell carcinoma of the bronchus. Cancer Chemother Pharmacol 10:205–207, 1983.

    Article  PubMed  CAS  Google Scholar 

  16. Johnson DH, Hande KR, Hainsworth JD, Greco FA: High-dose etoposide as single agent chemotherapy for small cell carcinoma of the lung. Cancer Treat Rep 67:957–958, 1983.

    PubMed  Google Scholar 

  17. Djerassi I: High-dose methotrexate (NSC-740) and citrovorum factor (NSC-3590) rescue: back ground and rationale. Cancer Chemother Rep Part 3, vol 3 (1):3–6, 1975.

    Google Scholar 

  18. Bryant BM, Jarman M, Ford HT, Smith IE: Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet ii: 657–660, 1980.

    Article  Google Scholar 

  19. Sleijfer DTh, Mulder NH, de Vries-Hospers HG, Fidler V, Nieweg HO, van der Waay D, van Saene HKF: Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer 16:859–869, 1980.

    PubMed  CAS  Google Scholar 

  20. Appelbaum FR, Herzig GP, Ziegler JL, Graw RG, Levine AS, Deisseroth AB: Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 52:85–95, 1978.

    PubMed  CAS  Google Scholar 

  21. McFarland W, Granvill MB, Dameshek W: Autologous bone marrow infusion as an adjunct in therapy of malignant disease. Blood 14:503–521, 1951.

    Google Scholar 

  22. Barbasch A, Higby DJ, Brass C, Bakri K, Karakousis C, Pontes JE, Wajsman LZ, Beckley S, Freeman A, Killion K, Burnett D: High-dose cyto-reductive therapy with autologous bone marrow transplantation in advanced malignancies. Cancer Treat Rep 67:143–148, 1983.

    PubMed  CAS  Google Scholar 

  23. Thomas ED, Storb R: Technique for human marrow grafting. Blood 36:507–515, 1970.

    PubMed  CAS  Google Scholar 

  24. de Vries EGE, Vriesendorp R, Meinesz AF, Mulder NH, Postmus PE, Sleijfer DTh: No narcosis for bone marrow harvest in autologous bone marrow transplantation. Blut 419–421, 1984.

    Google Scholar 

  25. Millar JL, Smith IE: The viability of marrow stored at 4°C. In: Autologous bone marrow transplantation and solid tumors. McVie JG, Dalieso O, Smith IE (eds.). European organization for research on treatment of cancer (EORTC) monograph series, volume 14:9–12. Raven Press, New York, 1984.

    Google Scholar 

  26. Lawrence HJ, Simone J, Aur RJA: Cyclophosphamide-induced hemorrhagic cystitis in children with leukemia. Cancer 36:1572–1576, 1975.

    Article  PubMed  CAS  Google Scholar 

  27. Storb R, Thomas ED, Weiden PL, Buckner CD, Clift RA, Fefer A, Fernando LP, Giblett ER, Goodell BW, Johnson L, Lerner KG, Neiman PE, Sanders JE: Aplastic anemia treated by allogeneic bone marrow transplantation: a report on 49 new cases from Seattle. Blood 48:817–841, 1976.

    PubMed  CAS  Google Scholar 

  28. Appelbaum FR, Straudren JA, Graw RG, Savage DD, Kent KM, Ferrans VJ, Herzig GP: Acute lethal carditis caused by high-dose combination chemotherapy. Lancet 1:58–62, 1976.

    Article  PubMed  CAS  Google Scholar 

  29. Buckner CD, Rudolph RH, Fefer A, Clift RA, Epstein RB, Funk DD, Neiman PF, Slighter SJ, Storb R, Thomas ED: High-dose cyclophosphamide therapy for malignant disease. Cancer 29:357–365, 1972.

    Article  Google Scholar 

  30. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J: Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 141:758–763, 1981.

    Article  PubMed  CAS  Google Scholar 

  31. Smith IE, Evans BD, Harland SJ: High-dose cyclophosphamide (7g/m2) with or without autologous bone marrow rescue after conventional chemotherapy in the treatment of patients with small cell lung cancer. Cancer Treatm Rev 10 (suppl A): 79–81, 1983.

    Article  Google Scholar 

  32. Litam JP, Dail DH, Spitzer G, Vellekoop L, Verma DS, Zander AR, Dicke KA: Early pulmonary toxicity after administration of high dose BCNU. Cancer Treat Rep 65:39–44, 1981.

    PubMed  CAS  Google Scholar 

  33. Weiss RB, Poster DS, Penta JS: The nitrosureas and pulmonary toxicity. Cancer Treatm Rev 8:111–125, 1981.

    Article  CAS  Google Scholar 

  34. Takvorian T, Parker LM, Canellos GP: Non-frozen or cryopreserved autologous bone marrow (ABM) rescue of BCNU-induced myelosuppression. Proc ASCO 22:424, 1981.

    Google Scholar 

  35. Holthuis JJM, Postmus PE, Sleijfer DTh, Mulder NH, Verleun H, van Oort WJ: Pharmacokinetics of etoposide (VP 16–213) after high-dose intravenous administration. 2nd European Conference on clinical oncology. 13 abstract 02–19, 1983.

    Google Scholar 

  36. Wolff SN, Fer MF, McKay C, Hainsworth J, Hande KR, Greco FA: High-dose VP16–213 and autologous bone marrow transplantation for refractory malignancies — a phase I study. J Clin Oncol 1:701–705, 1983.

    PubMed  CAS  Google Scholar 

  37. Postmus PE, Mulder NH, Sleijfer DTh, Meinesz AF, Vriesendorp R, de Vries EGE: High-dose VP16–213 (etoposide) for refractory malignancies; a phase I study. Cancer Treat Rep 68:1471–1474, 1984.

    PubMed  CAS  Google Scholar 

  38. de Vries EGE, Mulder NH, Postmus PE, Vriesendorp R, Willemse PHB, Sleijfer DTh. High-dose VM 26 (teniposide) for refractory malignancies; a phase I study. Cancer Treat Rep (in press).

    Google Scholar 

  39. Houston Jameson C, Solanki DL: Stevens Johnson syndrome associated with etoposide therapy. Cancer Treat Rep 67:1050–1051, 1983.

    Google Scholar 

  40. Postmus PE, de Vries EGE, de Vries-Hospers HG, Vriesendorp R, van Imhoff GW, Holthuis JJM, Smit Sibinga CTh, Sleijfer DTh, Mulder NH: Cyclophosphamide and VP16–213 with autologous bone marrow transplantation. A dose escalation study. Eur J Cancer 20:777–782, 1984.

    Article  CAS  Google Scholar 

  41. Douer D, Champlin RE, Ho WG, Sarna GP, Wells JH, Graze PR, Cline M J, Gale RP: High-dose combined-modality therapy and autologous bone marrow transplantation in resistant cancer. Am J Med 71:973–976, 1981.

    Article  PubMed  CAS  Google Scholar 

  42. Stewart P, Buckner CD, Thomas ED, Bagley C, Bensinger W, Clift RA, Appelbaum FR, Sanders J: Intensive chemoradiotherapy with autologous marrow transplantation for small cell carcinoma of the lung. Cancer Treat Rep 67:1055–1059, 1983.

    PubMed  CAS  Google Scholar 

  43. McElwain TJ, Hedley DW, Burton G, Clink HM, Gordon MY, Jarman M, Juttner CA, Millar JL, Milsted RAV, Prentice G, Smith JE, Spence D, Woods M: Marrow autotransplantation accelerates hematological recovery in patients with malignant melanoma treated with high-dose melphalan. Br J Cancer 40:72–80, 1979.

    Article  PubMed  CAS  Google Scholar 

  44. Tobias JS, Werner RS, Griffiths CT, Richman CM, Parker LM, Yankee RA: Cryopreserved autologous marrow infusion following high-dose cancer chemotherapy. Eur J Cancer 13:269–277, 1977.

    PubMed  CAS  Google Scholar 

  45. Abrams RA, Glaubiger D, Simon R, Lichter A, Deisseroth AB: Hematopoietic recovery in Ewing’s sarcoma after intensive combination therapy and autologous marrow infusion. Lancet 2:385–389, 1980.

    Article  PubMed  CAS  Google Scholar 

  46. Gorin NC, Donay L, David R, Stachowiak J, Parlier Y, Oppenheimer M, Najman A, Duhamel G: Delayed kinetics of recovery of haemopoiesis following autologous bone marrow transplantation. The role of excessively rapid marrow freezing rates after the release of fusion heat. Eur J Cancer 19:185–191, 1983.

    Google Scholar 

  47. Spitzer G, Verma DS, Fisher R, Zander A, Vellekoop L, Litam J, McCredie KB, Dicke KA: The myeloid progenitor cell — its value in predicting hematopoietic recovery after autologous bone marrow transplantation. Blood 55:317–323, 1980.

    PubMed  CAS  Google Scholar 

  48. Ihde DC, Simms EB, Matthews MJ, Cohen MH, Bunn PA, Minna JD: Bone marrow metastases in small cell carcinoma of the lung: Frequency, description and influence on chemotherapeutic toxicity and prognosis. Blood 53:677–686, 1979.

    PubMed  CAS  Google Scholar 

  49. Vindelov LL, Hansen HH, Christensen IJ, Spring-Thomsen M, Hirsch FR, Hansen M, Nissen NI: Clonal heterogeneity of small cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. Cancer Research 40:4295–4300, 1980.

    PubMed  CAS  Google Scholar 

  50. Norton L, Simon R: Tumour size, sensitivity to therapy and design of treatment schedules. Cancer Treat Rep 61:1307–1317, 1977.

    PubMed  CAS  Google Scholar 

  51. Postmus PE, Mulder NH, de Vries EGE, van Luyn M, Halie MR: Small cell lung cancer and the influence of chemotherapy on CFUcs in bone marrow. Cancer 53:396–400, 1984.

    Article  PubMed  CAS  Google Scholar 

  52. Frei E, III, Blum RH, Pitman SW, Kirkwood JM, Henderson IC, Skarin AT, Meyer RJ, Bast RC, Garnick MB, Parker LM, Canellos GP: High-dose methotrexate with leucovovin rescue: rationale and spectrum of antitumor activity. Am J Med 68:370–376, 1980.

    Article  PubMed  Google Scholar 

  53. Hande KR, Oldham RK, Fer MF, Richardson RL, Greco FA: Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer. Am J Med 73:413–419, 1982.

    Article  PubMed  CAS  Google Scholar 

  54. Ihde DC, Johnston-Early A, Carney DN, Cohen MH, Bunn PA, Pelsor FR, Minna JD: Lack of efficacy of high-dose methotrexate by 30-hour infusion in patients with progressive small cell carcinoma of the lung. Cancer Treat Rep 66:1223–1225, 1982.

    PubMed  CAS  Google Scholar 

  55. Humblet Y, Symann M, Bosly A, Delaunois L, Steyaert J, Francis C, Machiels J, Prignot J: Late intensification chemotherapy with autologous bone marrow infusion in small cell lung cancer: Preliminary results of a randomized trial. In: autologous bone marrow transplantation and solid tumors, McVie JG, Dalieso O, SMith IE (eds.) European organization for research on treatment of cancer (EORTC). Monograph series vol 14, page 97–103. Raven Press, New York, 1984.

    Google Scholar 

  56. Spitzer G, Dicke KA, Litam J, Verma DS, Zander A, Lanzotti V, Valdivieso M, McCredie KB, Samuels ML: High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors. Cancer 45:3075–3085, 1980.

    Article  PubMed  CAS  Google Scholar 

  57. Pico JL, Hayat M, Arriagada R, Baldeyrok P, le Chevalier T, Debre M: High-dose chemotherapy with autologous bone marrow transplantation in small cell lung cancer (SCLC). Personal communication 1984.

    Google Scholar 

  58. Postmus PE, Mulder NH, de Vries-Hospers HG, Mulder POM, Maas G, Meinesz AF, Sleijfer DTh, de Vries EGE: High-dose cyclophosphamide and high-dose VP16–213 for recurrent or refractory small cell lung cancer. A phase II study Eur J Cancer, (in press).

    Google Scholar 

  59. Rushing DA, Baldauf MC, Gehlsen JA, Kriesel DH, Koontz DP, Friedenberg WR: High-dose BCNU and autologous bone marrow reinfusion in the treatment of refractory or relapse small cell carcinoma of the lung (SCLC). Proc ASCO 3:217, abstract C846, 1984.

    Google Scholar 

  60. Spitzer G, Dicke KA, Verma DS, Zander A, McCredie KB: High-dose BCNU therapy with autologous bone marrow infusion. Preliminary observations. Cancer Treat Rep 63:1257–1263, 1979.

    PubMed  CAS  Google Scholar 

  61. Farha P, Spitzer G, Valdivieso M, Dicke KA, Zander A, Dhingra HM, Minnhaar G, Vellekoop L, Verma DS, Umsawasdi T, Chiuten D: High-dose chemotherapy and autologous bone marrow transplantation for the treatment of small cell lung carcinoma. Cancer 52:1351–1355, 1983.

    Article  PubMed  CAS  Google Scholar 

  62. Johnson DH, Wolff SN, Porter LL, Hainsworth JD, Hande KR, Greco FA: Combination high-dose (HD) VP 16–213 (E)/cyclophosphamide (C) chemotherapy without bone marrow transplantation for extensive stage small cell lung cancer. Personal communication, 1984.

    Google Scholar 

  63. Ihde DC, Lichter AS, Deisseroth AB, Bunn PA, Carney DN, Cohen MH, Makuch RW, Johnston-Early A, Minna JD: Late intensive combined modality (LIRX) with autologous bone marrow (ABM) infusion in extensive stage small cell lung cancer (SCLC). Personal communication 1984.

    Google Scholar 

  64. Kaye SB: VP 16 in small cell lung cancer: studies of the west of Scotland lung cancer group, incorporating high-dose chemotherapy, 1981–83. Personal communication, 1984.

    Google Scholar 

  65. Klastersky J, Nicaise C, Longeval E, Stryckmans P and the EORTC Lung Cancer Working party: Cisplatin, Adriamycin, and Etoposide (CAV) for remission induction of small-cell bronchogenic carcinoma. Cancer 50:652–658, 1982.

    Article  PubMed  CAS  Google Scholar 

  66. Klastersky J, Sculier JP, Debusscher L and the EORTC Lung Cancer Working party: Personal communication, 1984.

    Google Scholar 

  67. Spitzer G, Farha P, Dicke K, Valdivieso M, Murphy W, Zander A, Chiuten D, Dhingra H, Jefferies D, Umsawasdi T: High-dose intensification with autologous bone marrow transplantation (ABMT) in limited small cell bronchogenic carcinoma (SCBC). Proc ACSO 3:221, abstract C864, 1984.

    Google Scholar 

Download references

Authors
  1. Pieter E. Postmus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dirk Th. Sleijfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nanno H. Mulder
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Oncology II, Finsen Institute, 49 Strandsoulevarden, DK - 2100, Copenhagen, Denmark

    Heine H. Hansen

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Postmus, P.E., Sleijfer, D.T., Mulder, N.H. (1986). High-Dose Chemotherapy for Small Cell Lung Cancer. In: Hansen, H.H. (eds) Lung Cancer: Basic and Clinical Aspects. Cancer Treatment and Research, vol 28. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2295-5_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2295-5_13

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9414-6

  • Online ISBN: 978-1-4613-2295-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation